Theravance Biopharma, INC Form 4 insider transactions

Aziz Sawaf, SVP & CFO of Theravance Biopharma, acquired 37,500 ordinary shares through a Rule 10b5-1(c) plan.

Brett A. Grimaud, SVP, General Counsel and Secretary of Theravance Biopharma, Inc., acquired 37,500 ordinary shares.

Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, acquired 18,750 ordinary shares.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, sold ordinary shares totaling 31,067 units on March 16, 2026, under a pre-arranged 10b5-1 plan.

Theravance Biopharma CEO Rick E Winningham disposed of 74,975 ordinary shares to cover tax obligations arising from vested restricted stock units.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 20,672 ordinary shares to cover tax obligations from vested restricted stock units.

Aine Miller, SVP at Theravance Biopharma, disposed of 16,851 ordinary shares to cover tax liabilities from vested restricted stock units.

Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, reported a routine disposition of shares to cover tax obligations from vested restricted stock units.

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., reported a routine disposition of shares to cover tax obligations related to vested restricted stock units.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, sold 31,067 ordinary shares for approximately $18.75 per share under a pre-arranged 10b5-1 plan.

Eran Broshy, a director at Theravance Biopharma, sold 29,501 ordinary shares for approximately $590,020 on November 26, 2025, under a pre-arranged 10b5-1 trading plan.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 18,627 ordinary shares to cover tax liabilities from vested restricted stock units.

Aine Miller, SVP, Development & Head of IRE Office at Theravance Biopharma, disposed of 6,989 ordinary shares to satisfy tax obligations from restricted stock unit vesting.

Theravance Biopharma's SVP, General Counsel, and Secretary, Brett A. Grimaud, disposed of shares to cover tax obligations from vested restricted stock units.

Theravance Biopharma's SVP of Communications and Medical Affairs, Rhonda Farnum, disposed of 9,060 ordinary shares to cover tax obligations related to vested restricted stock units.

Theravance Biopharma CEO Rick Winningham disclosed recent share transactions, including gifts to a custodial account and shares withheld for tax obligations.

Theravance Biopharma Director Eran Broshy filed an amended Form 4 to correct the number of shares sold on November 11, 2025, under a Rule 10b5-1 trading plan.

Theravance Biopharma Director Eran Broshy sold 59,000 ordinary shares and exercised 14,000 stock options on November 11, 2025, under a pre-arranged trading plan.

Theravance Biopharma CEO Rick Winningham disposed of 15,394 ordinary shares to cover tax obligations from restricted stock unit vesting.

Theravance Biopharma's SVP & CFO, Aziz Sawaf, disposed of 9,368 ordinary shares at $13.39 each to cover tax liabilities from restricted stock unit vesting.

Aine Miller, SVP at Theravance Biopharma, disposed of 6,989 ordinary shares to cover tax obligations from restricted stock unit vesting.

A Theravance Biopharma executive disposed of shares to cover tax obligations from restricted stock unit vesting.

A Theravance Biopharma executive reported a future disposition of shares to cover tax obligations related to restricted stock unit vesting.

A senior executive at Theravance Biopharma, Inc. sold 10,000 ordinary shares for approximately $11.39 per share, executed under a pre-existing 10b5-1 trading plan.

Theravance Biopharma, Inc. CEO Rick E. Winningham reported gifting 20,000 ordinary shares, a transaction filed with the SEC on June 25, 2025.

Theravance Biopharma CEO Rick E. Winningham reported gifting 9,600 ordinary shares to a custodial account for his grandchildren, disclaiming beneficial ownership of these shares.

Rhonda Farnum, SVP of Commercial and Medical Affairs at Theravance Biopharma, Inc., sold 24,000 ordinary shares for $11 per share, as part of a pre-arranged 10b5-1 trading plan.

CEO Rick Winningham of Theravance Biopharma reports disposing of shares to cover tax obligations related to vesting restricted stock units.

Aziz Sawaf, SVP & CFO of Theravance Biopharma, disposed of 9,348 ordinary shares to cover tax obligations arising from vesting restricted stock units.

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., reports disposing of 9,743 ordinary shares to cover tax obligations related to vesting restricted stock units.